Reviewing Cyanotech Corporation (CYAN)’s and ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s results

Since Cyanotech Corporation (NASDAQ:CYAN) and ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership of both companies.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cyanotech Corporation 32.24M 0.58 3.18M -0.21 0.00
ZIOPHARM Oncology Inc. 1.74M 232.20 75.56M -0.54 0.00

Table 1 highlights Cyanotech Corporation and ZIOPHARM Oncology Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 has Cyanotech Corporation and ZIOPHARM Oncology Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Cyanotech Corporation -9.86% -13.5% -7.9%
ZIOPHARM Oncology Inc. -4,342.53% 58.6% -89.9%

Risk and Volatility

Cyanotech Corporation is 33.00% less volatile than S&P 500 because the stock has a beta of 0.67. From a competition point of view, ZIOPHARM Oncology Inc. has a 1.91 beta which is 91.00% more volatile compared to S&P 500.


1.8 and 0.4 are the respective Current Ratio and a Quick Ratio of Cyanotech Corporation. Its rival ZIOPHARM Oncology Inc.’s Current and Quick Ratios are 0.8 and 0.8 respectively. Cyanotech Corporation has a better chance of clearing its pay short and long-term debts than ZIOPHARM Oncology Inc.

Analyst Recommendations

Cyanotech Corporation and ZIOPHARM Oncology Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Cyanotech Corporation 0 0 0 0.00
ZIOPHARM Oncology Inc. 0 0 1 3.00

ZIOPHARM Oncology Inc. on the other hand boasts of a $5 consensus target price and a 97.63% potential upside.

Institutional and Insider Ownership

Institutional investors held 13.8% of Cyanotech Corporation shares and 41.4% of ZIOPHARM Oncology Inc. shares. Insiders held roughly 19.1% of Cyanotech Corporation’s shares. Comparatively, ZIOPHARM Oncology Inc. has 1.77% of it’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cyanotech Corporation -5.56% 6.06% -3.37% -12.73% -17.93% -11.82%
ZIOPHARM Oncology Inc. -8.06% 24.7% 14.07% -29.52% -29.03% -25.6%

For the past year Cyanotech Corporation has stronger performance than ZIOPHARM Oncology Inc.


On 8 of the 11 factors Cyanotech Corporation beats ZIOPHARM Oncology Inc.

Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition market worldwide. The companyÂ’s products include Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids; and Hawaiian BioAstin natural astaxanthin, a dietary antioxidant, which is used as a human nutraceutical and functional food ingredient to support and maintain the bodyÂ’s natural inflammatory response, enhance skin, and support eye and joint health. Cyanotech Corporation sells its products in bulk quantities to manufacturers, formulators, and distributors in the health foods and nutritional supplements markets; and as packaged consumer products to distributors, retailers, and direct consumers. The company also sells its products online at Cyanotech Corporation was founded in 1983 and is headquartered in Kailua-Kona, Hawaii.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to IntrexonÂ’s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma (GBM). Its synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer. The company, under its license agreement with The University of Texas MD Anderson Cancer Center, along with Intrexon hold license to certain technologies relating to novel chimeric antigen receptor (CAR) T cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer cells, and T cell receptors. It also has a research and development agreement with the National Cancer Institute utilizing Sleeping Beauty System to generate T cells receptors for the treatment of solid tumors. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.


Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.